Limits...
More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery.

Ohtori S, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kuniyoshi K, Aoki Y, Nakamura J, Miyagi M, Suzuki M, Kubota G, Inage K, Sainoh T, Sato J, Shiga Y, Abe K, Fujimoto K, Kanamoto H, Inoue G, Takahashi K - Asian Spine J (2015)

Bottom Line: Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-duration treatment group (p<0.05).Daily injection of teriparatide for bone union was more effective than oral administration of bisphosphonate.Furthermore, a longer period of teriparatide treatment for bone union was more effective than a shorter period of same treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

ABSTRACT

Study design: Retrospective case series.

Purpose: To examine the most effective duration of teriparatide use for spinal fusion in women with postmenopausal osteoporosis.

Overview of literature: We reported that daily subcutaneous injection of teriparatide (parathyroid hormone) significantly improved bone union after instrumented lumbar posterolateral fusion (PLF) in women with postmenopausal osteoporosis when compared with oral administration of bisphosphonate. However, the most effective duration of teriparatide use for spinal fusion has not been explored.

Methods: Forty-five women with osteoporosis diagnosed with degenerative spondylolisthesis from one of the three treatment groups were evaluated based on: short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 µg teriparatide), long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 µg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate). All patients underwent PLF with a local bone graft. Fusion rate and duration of bone union were evaluated 1.5 years after surgery.

Results: Bone union rate and average duration for bone union were 92% and 7.5 months in the long-duration treatment group, 80% and 8.5 months in the short-duration treatment group, and 70% and 10.0 months in the bisphosphonate treatment group, respectively. Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-duration treatment group (p<0.05).

Conclusions: Daily injection of teriparatide for bone union was more effective than oral administration of bisphosphonate. Furthermore, a longer period of teriparatide treatment for bone union was more effective than a shorter period of same treatment.

No MeSH data available.


Related in: MedlinePlus

Patient in teriparatide long-duration treatment group. (A) Myelogram before surgery. (B) The patient showed L3 and L4 degenerated spondylolisthesis and spinal stenosis. (C) X-ray at 15 months after surgery. Bilateral bone formation bridging the transverse processes between adjacent vertebrae was seen in this patient. (D, E) Computed tomography at 12 months after surgery. Facet fusions (arrows) were observed in this patient.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4522448&req=5

Figure 1: Patient in teriparatide long-duration treatment group. (A) Myelogram before surgery. (B) The patient showed L3 and L4 degenerated spondylolisthesis and spinal stenosis. (C) X-ray at 15 months after surgery. Bilateral bone formation bridging the transverse processes between adjacent vertebrae was seen in this patient. (D, E) Computed tomography at 12 months after surgery. Facet fusions (arrows) were observed in this patient.

Mentions: At 12 months follow-up by CT, 50% of facet joints had achieved bone union in the risedronate group; 61% had achieved union in the short-duration teriparatide treatment group; and 81% had achieved union in the long-duration treatment group. The rates of bone fusion in the long-duration teriparatide treatment group were significantly greater than the risedronate and short-duration treatment groups (p<0.05) (Table 2, Fig. 1).


More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery.

Ohtori S, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kuniyoshi K, Aoki Y, Nakamura J, Miyagi M, Suzuki M, Kubota G, Inage K, Sainoh T, Sato J, Shiga Y, Abe K, Fujimoto K, Kanamoto H, Inoue G, Takahashi K - Asian Spine J (2015)

Patient in teriparatide long-duration treatment group. (A) Myelogram before surgery. (B) The patient showed L3 and L4 degenerated spondylolisthesis and spinal stenosis. (C) X-ray at 15 months after surgery. Bilateral bone formation bridging the transverse processes between adjacent vertebrae was seen in this patient. (D, E) Computed tomography at 12 months after surgery. Facet fusions (arrows) were observed in this patient.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4522448&req=5

Figure 1: Patient in teriparatide long-duration treatment group. (A) Myelogram before surgery. (B) The patient showed L3 and L4 degenerated spondylolisthesis and spinal stenosis. (C) X-ray at 15 months after surgery. Bilateral bone formation bridging the transverse processes between adjacent vertebrae was seen in this patient. (D, E) Computed tomography at 12 months after surgery. Facet fusions (arrows) were observed in this patient.
Mentions: At 12 months follow-up by CT, 50% of facet joints had achieved bone union in the risedronate group; 61% had achieved union in the short-duration teriparatide treatment group; and 81% had achieved union in the long-duration treatment group. The rates of bone fusion in the long-duration teriparatide treatment group were significantly greater than the risedronate and short-duration treatment groups (p<0.05) (Table 2, Fig. 1).

Bottom Line: Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-duration treatment group (p<0.05).Daily injection of teriparatide for bone union was more effective than oral administration of bisphosphonate.Furthermore, a longer period of teriparatide treatment for bone union was more effective than a shorter period of same treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

ABSTRACT

Study design: Retrospective case series.

Purpose: To examine the most effective duration of teriparatide use for spinal fusion in women with postmenopausal osteoporosis.

Overview of literature: We reported that daily subcutaneous injection of teriparatide (parathyroid hormone) significantly improved bone union after instrumented lumbar posterolateral fusion (PLF) in women with postmenopausal osteoporosis when compared with oral administration of bisphosphonate. However, the most effective duration of teriparatide use for spinal fusion has not been explored.

Methods: Forty-five women with osteoporosis diagnosed with degenerative spondylolisthesis from one of the three treatment groups were evaluated based on: short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 µg teriparatide), long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 µg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate). All patients underwent PLF with a local bone graft. Fusion rate and duration of bone union were evaluated 1.5 years after surgery.

Results: Bone union rate and average duration for bone union were 92% and 7.5 months in the long-duration treatment group, 80% and 8.5 months in the short-duration treatment group, and 70% and 10.0 months in the bisphosphonate treatment group, respectively. Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-duration treatment group (p<0.05).

Conclusions: Daily injection of teriparatide for bone union was more effective than oral administration of bisphosphonate. Furthermore, a longer period of teriparatide treatment for bone union was more effective than a shorter period of same treatment.

No MeSH data available.


Related in: MedlinePlus